. Author manuscript; available in PMC: 2020 Sep 8.

Published in final edited form as: Hepatology. 2009 Apr;49(4):1335–1374. doi: 10.1002/hep.22759

Table 14.

Treatment According to Stages of Chronic Kidney Diseases²⁷³

Stage	Description	GFR (ml min⁻¹ 1.73 m⁻²)	Recommended Treatment
1.	Kidney damage with normal or increased GFR	≥90	^A
2.	Kidney damage with mild decrease GFR	60–90	^A
3.	Moderate decrease GFR	30–59	^B
4.	Severe decrease GFR	15–29	^B
5.	Kidney failure	<15	^B
5D.	Dialysis (hemo- or peritoneal)		^C

^A:

Routine combination therapy according to viral genotype.

^B:

Peginterferon alfa-2b, 1 μg/kg subcutaneously once weekly, or Peginterferon alfa-2a, 135 μg subcutaneously once weekly plus Ribavirin, 200–800 mg/day in two divided does starting with low dose and increasing gradually

^C:

Controversial: Standard interferon (2a or 2b) 3mU three times weekly, or Pegylated interferon alfa-2b, 1 μg/kg/week, or Pegylated interferon alfa-2a, 135 μg/kg/week ± Ribavirin in markedly reduced daily dose.

Abbreviation: GFR, glomerular filtration rate.